Healthier World with Quest Diagnostics podcast

49 - Decoding minimal residual disease (22 mins)

0:00
21:44
Rewind 15 seconds
Fast Forward 15 seconds

Episode summary

Minimal residual disease (MRD) testing is an emerging tool in precision oncology that can provide insights beyond traditional imaging and clinical assessment. In this episode, Rebecca Johnson Wheeler, MS, CGC, and Dr CK Wang explore how circulating tumor DNA (ctDNA) can be used to detect residual disease and discuss how MRD results may help inform recurrence risk, treatment response, and disease surveillance and explore the growing role of MRD testing in cancer care.

This episode will

  • Define minimal residual disease and describe how circulating tumor DNA (ctDNA) can be used to detect evidence of cancer that may remain after treatment  (4:08)
  • Differentiate tumor-informed and tumor agnostic MRD approaches to testing, and what to consider when selecting an MRD test. (5:57)
  • Explain the clinical significance of MRD results and its clinical utility in muscle invasive bladder cancer care through a case example (9:36)
  • Recognize current and emerging clinical applications of MRD testing (16:00)

Date: November 2026

Speaker(s): Rebecca Johnson Wheeler, MS, CGC; CK Wang, MD

Contributor(s): Rebecca Johnson Wheeler, MS, CGC; CK Wang, MD; Jared Snider, PhD; Mark Reed, PhD

 

Additional resources:

Quest Diagnostics Clinical Education Center

Haystack MRD

Ordering information:

Contact to order

Haystack MRD baseline

References:

National Comprehensive Cancer Network®. Bladder Cancer (Version 3.2026). Published August 2026. Accessed October 2, 2026. https://www.nccn.org

Tie J, Wang Y, Lo SN, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31(5):1509-1518. doi:10.1038/s41591-025-03579-w

Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA Analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261-2272. doi:10.1056/NEJMoa2200075

Powles T, Kann AG, Castellano D, et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N Engl J Med. 2025;393(24):2395-2408. doi:10.1056/NEJMoa2511885

Zhou H, Zhu L, Song J, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer. 2022;21(1):86. doi:10.1186/s12943-022-01556-2

 

More episodes from "Healthier World with Quest Diagnostics"